Paediatric Strategy Forum for medicinal product development of DNA damage response pathway inhibitors in children and adolescents with cancer: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration

Autor: Pearson, A.D.J., Federico, S., Gatz, S.A., Ortiz, M., Lesa, G., Scobie, N., Gounaris, I., Weiner, S.L., Weigel, B., Unger, T.J., Stewart, E., Smith, M., Slotkin, E.K., Reaman, G., Pappo, A., Nysom, K., Norga, K., McDonough, J., Marshall, L.V., Ludwinski, D., Ligas, F., Karres, D., Kool, M., Horner, T.J., Henssen, A., Heenen, D., Hawkins, D.S., Gore, L., Bender, J.G., Galluzzo, S., Fox, E., de Rojas, T., Davies, B.R., Chakrabarti, J., Carmichael, J., Bradford, D., Blanc, P., Bernardi, R., Benchetrit, S., Akindele, K., Vassal, G.

DNA damage response inhibitors have a potentially important therapeutic role in paediatric cancers; however, their optimal use, including patient selection and combination strategy, remains unknown. Moreover, there is an imbalance between the number

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=mdc______med::1710b7ed5065a0dad58ad299181a3dc3
http://edoc.mdc-berlin.de/23585/1/23585oa.pdf

Paediatric Strategy Forum for medicinal product development for acute myeloid leukaemia in children and adolescents : ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration

Autor: Pearson, ADJ, Zwaan, C.M., Kolb, EA, Karres, D, Guillot, J, Kim, SY, Marshall, L, Tasian, SK, Smith, M, Cooper, T, Adamson, PC, Barry, E, Benettaib, B, Binlich, F, Borgman, A, Brivio, E, Capdeville, R, Delgado, D, Faller, DV, Fogelstrand, L, Fraenkel, PG, Hasle, H, Heenen, D, Kaspers, G, Kieran, M, Klusmann, JH, Lesa, G, Ligas, F, Mappa, S, Mohamed, H, Moore, A, Morris, J, Nottage, K, Reinhardt, D, Scobie, N, Simko, S, Winkler, T, Norga, K, Reaman, G, Vassal, G

Publikováno v: European journal of cancer
Pearson, A D J, Zwaan, C M, Kolb, E A, Karres, D, Guillot, J, Kim, S Y, Marshall, L, Tasian, S K, Smith, M, Cooper, T, Adamson, P C, Barry, E, Benettaib, B, Binlich, F, Borgman, A, Brivio, E, Capdeville, R, Delgado, D, Faller, D V, Fogelstrand, L, Fraenkel, P G, Hasle, H, Heenen, D, Kaspers, G, Kieran, M, Klusmann, J H, Lesa, G, Ligas, F, Mappa, S, Mohamed, H, Moore, A, Morris, J, Nottage, K, Reinhardt, D, Scobie, N, Simko, S, Winkler, T, Norga, K, Reaman, G & Vassal, G 2020, ' Paediatric Strategy Forum for medicinal product development for acute myeloid leukaemia in children and adolescents : ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration ', European Journal of Cancer, vol. 136, pp. 116-129 . https://doi.org/10.1016/j.ejca.2020.04.038
European Journal of Cancer, 136, 116-129. Pergamon
European Journal of Cancer, 136, 116-129. Elsevier Ltd.

Purpose: The current standard-of-care for front-line therapy for acute myeloid leukaemia (AML) results in short-term and long-term toxicity, but still approximately 40% of children relapse. Therefore, there is a major need to accelerate the evaluatio

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::ea901e797ad2961db6c39007f2797adc
https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&origin=inward&scp=85087974955

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.